“I am optimistic about the results of the trial,” says Dr. Morales, professor emeritus in the Department of Urology at Queen’s University and director of the Queen’s University Centre for Applied Urological Research. “Positive results in the next phase of trials will move us very close to a far more effective bladder cancer treatment.”
Initial human trials found that Urocidin is effective and much safer than previous treatment options for cases of superficial bladder cancer that is not responsive to Bacillus Calmette-Guérin (BCG) therapy. A recent large North American clinical trial confirmed the initial findings, with 25 per cent of patients becoming disease-free after one year of therapy with the new drug. Patients also tolerated Urocidin well.
Dr. Morales spearheaded BCG as a bladder cancer treatment in the 1970s in collaboration with the Cancer Research Institute of New York. BCG provoked an immune response strong enough to eliminate some bladder cancers without chemicals. It was also the first effective agent approved by the FDA against solid tumors. BCG remains the first choice to treat superficial bladder cancer due to its superior efficacy over chemotherapy drugs; however, as a live bacterium, it has the potential for serious adverse effects.
Until the discovery of BCG as a bladder cancer therapy, the only alternative short of bladder removal was to put chemicals into the bladder.
Urocidin was developed by Bioniche Life Sciences Inc. A second Phase III clinical trial is underway, funded by Bioniche’s licensing partner, Endo Pharmaceuticals.
Christina Archibald | EurekAlert!
NIH scientists describe potential antibody treatment for multidrug-resistant K. pneumoniae
14.03.2018 | NIH/National Institute of Allergy and Infectious Diseases
Researchers identify key step in viral replication
13.03.2018 | University of Pittsburgh Schools of the Health Sciences
Animal photoreceptors capture light with photopigments. Researchers from the University of Göttingen have now discovered that these photopigments fulfill an...
On 15 March, the AWI research aeroplane Polar 5 will depart for Greenland. Concentrating on the furthest northeast region of the island, an international team...
The world’s second-largest ice shelf was the destination for a Polarstern expedition that ended in Punta Arenas, Chile on 14th March 2018. Oceanographers from...
At the 2018 ILA Berlin Air Show from April 25–29, the Fraunhofer Institute for Laser Technology ILT is showcasing extreme high-speed Laser Material Deposition (EHLA): A video documents how for metal components that are highly loaded, EHLA has already proved itself as an alternative to hard chrome plating, which is now allowed only under special conditions.
When the EU restricted the use of hexavalent chromium compounds to special applications requiring authorization, the move prompted a rethink in the surface...
At the ILA Berlin, hall 4, booth 202, Fraunhofer FHR will present two radar sensors for navigation support of drones. The sensors are valuable components in the implementation of autonomous flying drones: they function as obstacle detectors to prevent collisions. Radar sensors also operate reliably in restricted visibility, e.g. in foggy or dusty conditions. Due to their ability to measure distances with high precision, the radar sensors can also be used as altimeters when other sources of information such as barometers or GPS are not available or cannot operate optimally.
Drones play an increasingly important role in the area of logistics and services. Well-known logistic companies place great hope in these compact, aerial...
16.03.2018 | Event News
13.03.2018 | Event News
08.03.2018 | Event News
16.03.2018 | Earth Sciences
16.03.2018 | Physics and Astronomy
16.03.2018 | Life Sciences